Multiple myeloma bone disease: pathophysiology of osteoblast inhibition
Open accessAbstract
Multiple myeloma (MM) is a plasma cell malignancy characterized by a high capacity to induce osteolytic bone lesions. Bone destruction in MM results from increased osteoclast formation and activity that occur in close proximity to myeloma cells. However, histomorphometric studies have demonstrated that MM patients with osteolytic bone lesions have lower numbers of osteoblasts and decreased bone formation. This impaired bone formation plays a critical role in the bone-destructive process. Recently, the biologic mechanisms involved in the osteoblast inhibition induced by MM cells have begun to be elucidated. In this article, the pathophysiology underlying osteoblast inhibition in MM is reviewed.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
An increase in osteoclastic formation and a decrease in osteoblastic formation describe altered bone remodeling in multiple myeloma.
“An increase in osteoclastic formation and a decrease in osteoblastic formation describe altered bone remodeling [42, 43].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [42]
Bone remodeling mechanisms become uncoupled in multiple myeloma, leading to the development of osteolytic bone lesions.
“Bone remodeling mechanisms become uncoupled in MM, leading to the development of osteolytic bone lesions.”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [42]
Myeloma cells prevent mesenchymal stromal cells from differentiating into mature osteoblasts.
“According to reports, myeloma cells prevent MSCs from differentiating into mature osteoblasts [42, 276, 277].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [42]
Cites
Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation
Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., & Karsenty, G. (1997) · Cell · doi:10.1016/s0092-8674(00)80257-3 · Cited by 4,246 · see citing works
Canonical WNT Signaling Promotes Osteogenesis by Directly Stimulating Runx2 Gene Expression
Gaur, T., Lengner, C. J., Hovhannisyan, H., Bhat, R. A., Bodine, P. V. N., Komm, B. S., Javed, A., van Wijnen, A. J., Stein, J. L., Stein, G. S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500608200 · Cited by 1,170 · see citing works
Giuliani, N., Colla, S., Sala, R., Moroni, M., Lazzaretti, M., La Monica, S., Bonomini, S., Hojden, M., Sammarelli, G., Barillè, S., et al. (2002) · Blood · doi:10.1182/blood-2002-04-1121 · Cited by 270 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
Solimando, A. G., Malerba, E., Leone, P., Prete, M., Terragna, C., Cavo, M., & Racanelli, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973836 · Cited by 65 · see citing works
Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway
Atsuta, I., Liu, S., Miura, Y., Akiyama, K., Chen, C., An, Y., Shi, S., & Chen, F.-M. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt322 · Cited by 57 · see citing works
Chiu, M., Toscani, D., Marchica, V., Taurino, G., Costa, F., Bianchi, M. G., Andreoli, R., Franceschi, V., Storti, P., Burroughs-Garcia, J., et al. (2020) · Cancers · doi:10.3390/cancers12113267 · Cited by 42 · see citing works
Self-citationKamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03741-x · Cited by 27 · see citing works
“According to reports, myeloma cells prevent MSCs from differentiating into mature osteoblasts [42, 276, 277].”
The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease
Lungu, O., Toscani, D., Burroughs-Garcia, J., & Giuliani, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054893 · Cited by 10 · see citing works
Self-citation
- Authors
- Giuliani, N., Rizzoli, V., & Roodman, G. D.
- Affiliations
- University of Parma (IT)
- ORCID
- Giuliani, Nicola
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-12-15
- Volume
- 108
- Issue
- 13
- Pages
- 3992-3996
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2074174622
- Cited by
- 302
- References
- 3
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 11 · 2022: 10 · 2021: 8 · 2020: 19 · 2019: 19 · 2018: 23 · 2017: 20 · 2016: 15 · 2015: 12 · 2014: 10 · 2013: 12 · 2012: 20
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- Multiple Myeloma Research Foundation
- International Myeloma Foundation
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- multiple myeloma, bone disease, osteoblast inhibition, osteolytic lesions, osteoclasts, bone formation, bone destruction, pathophysiology, plasma cell malignancy
- MeSH terms
- Humans, Multiple Myeloma, Osteoblasts, Osteoclasts, Osteogenesis, Osteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
